الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
This study was carried out to investigate the potential effects of vitamin B12, sitagliptin and their combinations with DOX on Ehrlich solid tumour mode This study was carried out on female adult Swiss albino mice. Mice were injected subcutaneously with 5 × 105 cells (suspended into 0.1 ml normal saline per mouse) into the right hind limb (thigh). At the 5th day of tumor induction, the tumor volume was measured and repeated every five days for a period of 21 days to compare tumor growth among different experimental groups The present data demonstrated that administration of DOX, B12 before EAC, sitagliptin (10 mg/kg), sitagliptin (20 mg/kg) and their combinations with DOX caused a significant inhibition of tumour growth and increase of survival time. On the other hand, MDA, TNF-α and NF-KB levels were significantly decreased while TAC was significantly increased in all treatment groups except DOX compared to positive control group. Besides, this study showed an increase in the level of caspase-3 in all treatment groups compared to control group indicating increased level of apoptosis and decreased proliferation of cancer cells as further confirmed by tumor histopathology. However, the use of B12 after EAC was the least effective in treatment of tumour. Vitamin B12 and sitagliptin can be used in combination with Dox that could benefit patients with different cancers. However, further research is needed in order to fully understand the inhibitory effects of B12, sitagliptin and/or DOX on progression and/or treatment of human malignancies before considering clinical trials.